Mumbai: Veterinary vaccine manufacturer Hester Biosciences reported a 71% year-on-year rise in consolidated net profit to ₹14.33 crore for the quarter ended September 2025, despite a 15% decline in revenues to ₹70.96 crore. Operational challenges in its subsidiaries in Nepal and Africa have been the biggest drag on the company’s financials.
Additionally, slower offtake from institutional orders, primarily from the government’s immunisation programs for PPR and Lumpy Skin Disease for livestock, has also been attributed to the mixed results.
The company has reached important milestones this quarter, including authorization for its H9N2 poultry vaccine and the introduction of feed supplements and disinfectants.
Hester’s India operations contributed to the majority of its earnings, accounting for almost 90% of the pie. Its African subsidiary has continued to face logistical and distribution constraints, yet its revenues have increased 94% year on year. The company’s Nepal division, however, remains a drag on the company, recording a net loss of ₹10.99 million for this quarter, as against a profit of ₹8.20 million in the preceding quarter, mostly due to temporary disruptions due to the political uncertainties there.
“While our consolidated revenues faced headwinds due to delays in government immunization programs, our focus on operational efficiency and cost management has yielded significant bottom-line growth. The Poultry Healthcare Division continues to perform well, and we are optimistic about the growth potential of our newly authorized H9N2 vaccine.” Rajiv Gandhi, CEO & Managing Director, Hester Biosciences, said.
